Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.

The objective of the study was to evaluate the efficacy and safety of fluvastatin in patients with hypercholesterolemia, including heterozygous familial hypercholesterolemia, in a 1-year study (a 12-week open assessment, followed by 40 weeks of active treatment). Of the 337 patients enrolled in the study, the effects of fluvastatin were analyzed in 296 patients at baseline and at 12 weeks. Of these, 265 were receiving 20 mg/day fluvastatin at week 12 and in 20 patients the dose had been increased to 30 mg/day; 11 patients violated the dosing protocol. A total of 229 patients continued into the 40-week, long-term phase, and 212 patients were analyzed at baseline and after 24 and 52 weeks. At the end of treatment, 153 evaluable patients were still taking 20 mg/day fluvastatin, 1 was taking 10 mg/day, and 48 patients were taking 30 mg/day, and 10 were taking 40 mg/day. In the 20 mg/day fluvastatin group, low density lipoprotein cholesterol (LDL-C) levels decreased by 24.1% at week 12 and by 29.3% at week 52. In those patients requiring the higher doses, the corresponding reductions in LDL-C were 20.2% (week 12) and 26.7% (week 52). Total cholesterol was also reduced at week 12 by 17.0% (20 mg/day) and 15.7% (20-30 mg/day), and at week 52 by 20.4% (< or = 20 mg/day) and 19.2% (> or = 30 mg/day). Throughout the study, fluvastatin was generally well tolerated and no serious clinical adverse events were observed. In conclusion, long-term treatment of hypercholesterolemia with fluvastatin at dosages of 20-40 mg daily can be considered both safe and effective.
AuthorsT Teramoto, Y Goto, K Kurokawa, H Nakamura, S Yoshida, Y Saito, N Nakaya, H Itakura, F Takaku, N Yamada
JournalThe American journal of cardiology (Am J Cardiol) Vol. 76 Issue 2 Pg. 33A-36A (Jul 13 1995) ISSN: 0002-9149 [Print] UNITED STATES
PMID7604794 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Anticholesteremic Agents
  • Apolipoproteins A
  • Apolipoproteins B
  • Apolipoproteins E
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Placebos
  • Triglycerides
  • fluvastatin
  • Cholesterol
  • Hydroxymethylglutaryl CoA Reductases
  • Anticholesteremic Agents (administration & dosage, therapeutic use)
  • Apolipoproteins A (blood)
  • Apolipoproteins B (blood)
  • Apolipoproteins E (blood)
  • Cholesterol (blood)
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Fatty Acids, Monounsaturated (administration & dosage, therapeutic use)
  • Humans
  • Hydroxymethylglutaryl CoA Reductases (administration & dosage, therapeutic use)
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypercholesterolemia (blood, drug therapy)
  • Hyperlipoproteinemia Type II (blood, drug therapy)
  • Indoles (administration & dosage, therapeutic use)
  • Japan
  • Longitudinal Studies
  • Middle Aged
  • Placebos
  • Safety
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: